Skip to main content

Table 1 Patient and tumor characteristics

From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

Characteristic All (n = 38) Cohort 1 (HER2-negative) (n = 9) Cohort 2 (HER2-positive) (n = 29)
No. of patients (%) No. of patients (%) No. of patients (%)
Age, years
 Median (range) 48 (31–62) 46 (31–57) 48 (32–62)
Sex
 Female 38 (100) 9 (100) 29 (100)
 Male 0 (0) 0 (0) 0 (0)
Race
 White 34 (89) 8 (89) 26 (90)
 Black or African-American 1 (3) 1 (11) 0 (0)
 Asian 3 (8) 0 (0) 3 (10)
Ethnicity
 Hispanic or Latino 1 (3) 0 (0) 1 (3)
 Non-Hispanic 37 (97) 9 (100) 28 (97)
ECOG PS at baseline
 0 24 (63) 4 (44) 20 (69)
 1 9 (24) 3 (33) 6 (21)
 2 5 (13) 2 (22) 3 (10)
Stage at initial diagnosis
 I 5 (13) 1 (11) 4 (14)
 II 13 (34) 4 (44) 9 (31)
 III 7 (18) 1 (11) 6 (21)
 IV 13 (34) 3 (33) 10 (34)
Receptor status at initial diagnosis
 ER and/or PR+, HER2-negative 7 (18) 5 (56) 2 (7)b
 ER and/or PR+, HER2-positive 14(37) 1 (11)a 13 (45)
 ER and PR negative, HER2-positive 14(37) 0 (0) 14 (48)
 ER, PR, and HER2-negative 3 (8) 3 (33) 0 (0)
Disease-free interval
  < 2 years 22 (58) 7 (78) 15 (52)
  > 2 years 16 (42) 2 (22) 14 (48)
Interval from metastatic diagnosis to CNS diagnosis (median [months], range) 14.8 (0–107) 5.9 (0–44.7) 16.6 (0–107)
Interval from CNS diagnosis to study entry (median [months], range) 15.7 (0.2–63.6) 11.0 (0.4–25.5) 19.8 (0.2–63.6)
Number of metastatic disease sites (median, range) 4 (1–5) 4 (1–5) 4 (1–5)
Sites of disease
 CNS 38 (100) 9 (100) 29 (100)
 Lung or pleural effusion 19 (50) 6 (67) 13 (45)
 Liver 17 (45) 4 (44) 13 (45)
 Bone 26 (68) 7 (78) 19 (66)
 Breast or chest wall 5 (13) 1 (11) 4 (14)
 Other 15 (39) 4 (44) 11 (38)
  Median (range) Median (range) Median (range)
Baseline CNS disease volume (in cc) 5.3 (0.7, 58.8) 8.2 (2.1, 24.7) 3.6 (0.7, 58.8)
  No. of patients (%) No. of patients (%) No. of patients (%)
Number of target CNS lesions
 1 9 (24) 2 (22) 7 (24)
 2 14 (37) 2 (22) 12 (41)
 3 7 (18) 3 (33) 4 (14)
 4 6 (16) 1 (11) 5 (17)
 5 2 (5) 1 (11) 1 (3)
  Median (range) Median (range) Median (range)
Size of target CNS lesions (in mm) 15.4 (10, 60.5) 16 (11.7, 40.9) 14.4 (10, 60.5)
  1. a One patient with ER-positive, HER2-positive breast cancer was entered in cohort 1 because of prior intolerance to trastuzumab and was treated with carboplatin and bevacizumab (without trastuzumab)
  2. bTwo patients had ER-positive, HER2-negative breast cancer at diagnosis but subsequent biopsy at recurrence showed HER2-positive disease
  3. Abbreviations: CNS central nervous system, ECOG PS Eastern Cooperative Oncology Group Performance Status, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor